New York Oncology Hematology’s multidisciplinary facility will provide a “coordination of care doesn’t really exist locally ...

CHICAGO — Counties in the U.S. with the highest environmental burden, such as increased pollution, had significantly higher cancer incidence among multiple malignancy types compared with areas ...

Heme Malignancies Program: TScan’s two lead TCR-T therapy candidates, TSC-100 and TSC-101, are designed to treat residual disease and prevent relapse in patients with acute myeloid leukemia (AML ...

Attivare will use MSR biomaterial scaffolds like this to first develop treatments for patients with solid tumors and heme malignancies who do not respond to immunotherapies yet. The immune ...

"This is an exciting year for TScan as we advance our mission of bringing life-changing T-cell therapies to patients with both heme and solid tumor malignancies,” said Gavin MacBeath, Ph.D ...